Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


From Bedside To Bench: A New Paradigm For Assessing New Treatments

Executive Summary

It is time for payers to stop passively accepting uncertainty and instead help to generate evidence on new medicines, says Hans-Georg Eichler from Austria’s association of insurers.

You may also be interested in...

Added Benefit For Orphans Is ‘Fictitious’ Says German HTA Body

Industry has warned that reforming the system for evaluating orphan drugs could have serious consequences for patient access.

COVID-19 Pandemic Means Another Delay For Canadian Pricing Reforms

Industry has have welcomed another delay to the implementation of drug pricing reforms that aim to lower Canadian drugs prices.

French Consortium Pioneers New AMR Development Model

A new consortium that has won funding from the French government will focus on developing new treatments, diagnostics and surveillance and make sure that these approaches are properly valued by involving health economists in new drug development.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts